|
Compound class:
Antibody
Comment: Adimanebart is an anti-muscle associated receptor tyrosine kinase (MuSK) monoclonal antibody with agonist action. It was designed to treat neuromuscular diseases, by improving impaired function at the neuromuscular junction in patients with conditions such as congenital myasthenia,myasthenia gravis and ALS. The goal of this approach is to reduce muscle weakness and fatigability. This may be the INN for argenx's clinical candidate ARGX-119 [1].
|
| Bioactivity Comments |
| ARGX-119 binds with high affinity to the Frizzled-like domain of human MuSK [1]. It cross-reacts with non-human primate, rat, and mouse MuSK. |
